for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UCB SA

UCB.BR

Latest Trade

69.52EUR

Change

3.08(+4.64%)

Volume

220,844

Today's Range

66.50

 - 

69.70

52 Week Range

62.26

 - 

80.06

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
66.44
Open
67.02
Volume
220,844
3M AVG Volume
6.98
Today's High
69.70
Today's Low
66.50
52 Week High
80.06
52 Week Low
62.26
Shares Out (MIL)
188.37
Market Cap (MIL)
13,004.65
Forward P/E
14.85
Dividend (Yield %)
1.24

Next Event

Q3 2019 Ucb SA Earnings Release

Latest Developments

More

Ra Pharmaceuticals - If Deal Is Terminated, Co May Be Required To Pay UCB S.A. A Termination Fee Of $75 Mln In Cash

UCB Agrees To Acquire Ra Pharmaceuticals For 2.1 Billion Dollars

UCB H1 Revenue Up At 2.3 Billion Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Industry

Major Drugs

Contact Info

Allee de la Recherche, 60

+32.2.5599999

https://www.ucb.com

Executive Leadership

Jean-Christophe Tellier

Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Evelyn Diego du Monceau de Bergendal

Non-Executive Chair of the Board

Pierre L. Gurdjian

Independent Non-Executive Vice Chairman of the Board

Detlef Thielgen

Executive Vice President, Chief Financial Officer, Member of the Executive Committee

Charl van Zyl

Executive Vice President, Chief Operating Officer, Member of the Executive Committee

Key Stats

2.63 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

4.2K

2017

4.5K

2018

4.6K

2019(E)

4.7K
EPS (EUR)

2016

3.190

2017

4.820

2018

4.780

2019(E)

4.503
Price To Earnings (TTM)
19.25
Price To Sales (TTM)
2.78
Price To Book (MRQ)
1.94
Price To Cash Flow (TTM)
13.28
Total Debt To Equity (MRQ)
21.41
LT Debt To Equity (MRQ)
15.45
Return on Investment (TTM)
8.31
Return on Equity (TTM)
6.55

Latest News

Latest News

Belgium's UCB to buy Ra Pharmaceuticals in $2.1 billion cash deal

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.

Belgium's UCB to buy Ra Pharmaceuticals for $2.1 bln

UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.

Drugmaker UCB backs Brexit Britain with 1 billion pound investment

Belgian drugmaker UCB <UCB.BR> expects to invest about 1 billion pounds in Britain over the next five years, throwing its support behind the country's life sciences sector despite Brexit uncertainty.

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®

* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

BRIEF-UCB Q1 Revenue Down At 1.07 Billion Euros

* FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION

BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen

* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN

BRIEF-UCB Acquires Element Genomics

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

BRIEF-UCB: Publication On Cimzia® Shows Psoriatic Arthritis Patients Achieved Treatment Targets

* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS

BRIEF-UCB Files For Acceptance With China Food And Drug Administration For Cimzia

* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

BRIEF-UCB SA U.S. Food And Drug Administration (FDA) Approves Label Change For UCB’S Cimzia®

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LABEL CHANGE FOR UCB’S CIMZIA®

BRIEF-UCB FY Net Sales Up At 4.18 Billion Euros

* FY: REVENUE EUR 4.53 BILLION VERSUS EUR 4.43 BILLION IN REUTERS POLL, NET SALES EUR 4.18 BILLION VERSUS EUR 3.83 BILLION YEAR AGO

BRIEF-UCB To Present Phase 2b Findings For Bimekizumab

* UCB ADVANCES PSORIASIS PIPELINE WITH POSITIVE DATA AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD 2018)

BRIEF-UCB Announces That EMA Has Approved Label Change For Cimzia

* LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING Source text : http://bit.ly/2Fe7JUV Further company coverage: (Gdynia Newsroom)

BRIEF-UCB Announces European Medicines Agency Accepts Filing For Evenity

* EUROPEAN MEDICINES AGENCY ACCEPTS FILING FOR EVENITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-UCB Announces Positive Top Line Results Of Phase 2b Bimekizumab Study

* BIMEKIZUMAB DEMONSTRATES IMPRESSIVE JOINT AND SKIN RESPONSES FOR PSORIATIC ARTHRITIS PATIENTS

BRIEF-UCB Bimekizumab Announces Results For Phase 2b Of BE Agile Study

* BIMEKIZUMAB ADVANCES WITH SIGNIFICANT RESULTS IN ANKYLOSING SPONDYLITIS PATIENTS

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

BRIEF-UCB 9-month revenue up at 3.3 billion euros, 2017 outlook increased

* 9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION

BRIEF-‍Partners Connected Health and UCB announce epilepsy partnership​

* PARTNERS CONNECTED HEALTH AND UCB ANNOUNCE COLLABORATION TO DEVELOP HEALTHCARE SOLUTIONS TO SUPPORT PEOPLE LIVING WITH EPILEPSY Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up